BALA CYNWYD, Pa., May 1, 2013 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Ebix, Inc. ("Ebix" or the "Company") (Nasdaq: EBIX) relating to the proposed acquisition Goldman, Sachs & Co. ("Goldman").
Click here to learn more about the investigation http://brodsky-smith.com/579-ebix-ebix-inc.html, or call: 877-534-2590.
Under the terms of the transaction, Ebix shareholders will receive only $20.00 in cash for each share of Ebix stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Ebix for not acting in the Company's shareholders' best interests in connection with the sale process. The transaction may undervalue Ebix and will result in loss for many long term Ebix shareholders. For example, Ebix stock traded at $23.06 per share as recently as November 1, 2012 and traded at $26.19 per share on February 7, 2012. In addition, an analyst has set a price target for Ebix stock at $24.00 per share.
If you own shares of Ebix stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at email@example.com visiting http://brodsky-smith.com/579-ebix-ebix-inc.html, by calling toll free 877-LEGAL-90.Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.